3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
222
Colorectal Neoplasms
196
Rectal Neoplasms
174
Stomach Neoplasms
116
Pancreatic Neoplasms
100
Neoplasm Metastasis
77
Colonic Neoplasms
59
Neoplasms
50
Esophageal Neoplasms
39
Triple Negative Breast Neoplasms
38
Nasopharyngeal Carcinoma
28
Biliary Tract Neoplasms
27
Cholangiocarcinoma
22
Gallbladder Neoplasms
20
Locally Advanced Rectal Cancer
17
Carcinoma, Hepatocellular
17
Adenocarcinoma
15
Gastrointestinal Neoplasms
13
Colorectal Cancer Metastatic
13
Head and Neck Neoplasms
12
Bile Duct Neoplasms
12
Adenocarcinoma Of Esophagus
12
Esophageal Squamous Cell Carcinoma
11
Breast Neoplasms, Male
11
Brain Neoplasms
11
Liver Neoplasms
10
Carcinoma, Renal Cell
10
Neuroendocrine Tumors
9
Unspecified Adult Solid Tumor, Protocol Specific
8
Squamous Cell Carcinoma of Head and Neck
8
Interventions
Cyclophosphamide
2
pembrolizumab
1
guadecitabine
1
Sutures
1
Surgical Instruments
1
Oxaliplatin
1
Oviposition
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Drainage
1
Colonoscopy
1
Chemoradiotherapy
1
Cetuximab
1
Capecitabine
1
Aspirin
1
Ascorbic Acid
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rectal Diseases
×
Capecitabine
×
Clear all
NCT04080843
2022-07-13
ALTER-C-002
Zhejiang University
Phase 2
Completed
30 enrolled